| 2024/04/19 19:15:25 | |
|---|---|
| Price | |
| 94.81 EUR | |
| Difference | -1.07% (-1.03) |
General attributes
| ISIN | US60770K1079 |
| Symbol | MRNA |
| Exchange | Tradegate |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 36,695 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 94.96 EUR (300) |
| Ask (Ask size) | 95.16 EUR (300) |
| Open | 95.26 EUR |
| High | 96.60 EUR |
| Low | 94.03 EUR |
| Close (prev. day) | 95.84 EUR |
| VWAP | 95.21376 EUR |
| Volume (pcs) | 2,673 |
| Trading volume | 254,506.38 |
| Number of trades | 58 |
| Last size | 75 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: MODERNA INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/19 19:15:25 | |
|---|---|
| Price | |
| 94.81 EUR | |
| Difference | -1.07% (-1.03) |
General attributes
| ISIN | US60770K1079 |
| Symbol | MRNA |
| Exchange | Tradegate |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 36,695 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 94.96 EUR (300) |
| Ask (Ask size) | 95.16 EUR (300) |
| Open | 95.26 EUR |
| High | 96.60 EUR |
| Low | 94.03 EUR |
| Close (prev. day) | 95.84 EUR |
| VWAP | 95.21376 EUR |
| Volume (pcs) | 2,673 |
| Trading volume | 254,506.38 |
| Number of trades | 58 |
| Last size | 75 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +17.41% | -26.29% | -32.78% |
| Perf (abs.) | +14.21 | -34.18 | -46.74 |
| Beta | 1.51 | 1.03 | 1.28 |
| Volatility | 54.81 | 49.23 | 64.64 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 97.43 EUR (4,485) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 97.15 EUR (8,490) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 89.62 EUR (10,092) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 96.33 EUR (7,337) |
| YTD High | date | 106.26 EUR (2024/04/09) |
| YTD Low | date | 78.62 EUR (2024/02/14) |
| 52 Weeks High | date | 133.40 EUR (2023/05/24) |
| 52 Weeks Low | date | 58.76 EUR (2023/11/02) |
All listings for MODERNA INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Berlin | 2024/04/19 | 19:05 | 95.03 EUR | 0.00 | 14 |
| Duesseldorf | 2024/04/19 | 16:30 | 96.36 EUR | 0.00 | 4 |
| Euronext Milan MTF Global Equity Market | 2024/04/19 | 17:44 | 95.87 EUR | 0.05 | 20 |
| Euronext Milan MTF Trading After Hours | 2024/04/19 | 18:16 | 98.73 EUR | 0.01 | 1 |
| Frankfurt | 2024/04/19 | 16:09 | 96.22 EUR | 0.02 | 6 |
| Hamburg | 2024/04/19 | 13:48 | 95.12 EUR | 0.02 | 3 |
| Hanover | 2024/04/19 | 08:00 | 94.52 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/04/19 | 17:30 | 102.13 USD | 0.00 | 6 |
| Munich | 2024/04/19 | 08:09 | 95.37 EUR | 0.00 | 1 |
| Nasdaq | 2024/04/19 | 19:21 | 101.35 USD | 116.54 | 20,994 |
| Stuttgart | 2024/04/19 | 17:06 | 96.12 EUR | 0.00 | 3 |
| Tradegate | 2024/04/19 | 19:15 | 94.81 EUR | 0.25 | 58 |
| Vienna Stock Exchange | 2024/04/19 | 17:32 | 96.03 EUR | 0.00 | 2 |
| Xetra | 2024/04/19 | 17:35 | 95.99 EUR | 0.28 | 74 |
Company Logo
Contact Details
| MODERNA INC. |
| - - |
| 200 Technology Square - 02139 Cambridge |
| Telefon: +1-617-714-6500 |
| Fax: +617-583-1998 |
| E-mail: info@modernatx.com |
PDF Downloads
| Company report: MODERNA INC. | |
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. |
Members of Management Board
| Noubar Afeyan | Chairman of Board of Directors |
| Elizabeth Nabel | Member of Board of Directors |
| Francois Nader | Member of Board of Directors |
| Robert Langer | Member of Board of Directors |
| Sandra Horning | Member of Board of Directors |
| Elizabeth Tallett | Member of Board of Directors |
| Paul Sagan | Member of Board of Directors |
| Stephen Berenson | Member of Board of Directors |
| Stéphane Bancel | Chairman of Managing Board |
| Brad Miller | Member of Executive Committee |
| Jamey Mock | Member of Executive Committee |
| Jerh Collins | Member of Executive Committee |
| Kate Cronin | Member of Executive Committee |
| Shannon Thyme Klinger | Member of Executive Committee |
| Stephen Hoge | Member of Executive Committee |
| Tracey Franklin | Member of Executive Committee |